Evidence map›Paper›PMID 37314647›Full record

Trial reportInternational urology and nephrology2023

The effect of adding Montelukast to oxybutynin on daily urination in children with pollakiuria: a randomized clinical trial.

Ali Arjmand Shabestari, Hamide Bakhtiari, Fatemeh Dorreh, Parsa Yousefichaijan, Amir Almasi-Hashiani

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International urology and nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ali Arjmand ShabestariDepartment of Pediatrics, School of Medicine, Arak University of Medical Sciences, Arak, Iran.ORCID http://orcid.org/0000-0001-6499-1067
Hamide BakhtiariStudents Research Committee, Arak University of Medical Sciences, Arak, Iran.
Fatemeh DorrehDepartment of Pediatrics, School of Medicine, Arak University of Medical Sciences, Arak, Iran.ORCID http://orcid.org/0000-0003-2568-9169
Parsa YousefichaijanDepartment of Pediatrics, School of Medicine, Arak University of Medical Sciences, Arak, Iran.ORCID http://orcid.org/0000-0003-1196-1264
Amir Almasi-HashianiInfectious Disease Research Center (IDRC), Arak University of Medical Sciences, Arak, Iran. Amiralmasi2007@gmail.com.ORCID http://orcid.org/0000-0003-4434-561X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePollakiuria is defined as a change in the pattern of daily urination. Students have mentioned wetting their pants at school as the third tragic event after the death of a parent or going blind. In this study, the effect of adding Montelukast to oxybutynin on the improvement of urinary symptoms of patients with pollakiuria was studied. MATERIALS AND

methodsThis study was a pilot clinical trial in which children with pollakiuria aged 3-18 years old were included. These children were randomly divided into two groups of intervention (Montelukast plus oxybutynin) and the control group (only oxybutynin). At the beginning and the end of the study (after 14 days), mothers were asked about the frequency of daily urination. Finally, the gathered data were compared between two groups.

resultsIn the present study, 64 patients were examined in two intervention and control groups (32 in each group). The results revealed that although significant changes were observed in both groups before and after intervention, the average changes in the intervention group were significantly higher (p = 0.014).

conclusionThe results of this study showed that adding montelukast to oxybutynin has a significant decrease in frequency of daily urination in patients with pollakiuria, although further studies are recommended in this area.

Indexed as

Muscarinic AntagonistsUrinationAcetatesAdolescentChildChild, PreschoolCyclopropanesDouble-Blind MethodHumansMandelic AcidsQuinolinesSulfidesTreatment OutcomeAcetatesCyclopropanesMandelic AcidsmontelukastMuscarinic AntagonistsoxybutyninQuinolinesSulfidesChildrenMontelukastPollakiuriaUrinary incontinenceUrinary symptoms

Identifiers

PMID37314647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.